The efficacy of HPV 16/18 vaccines on sexually active 18–23 year old women and the impact of HPV vaccination on organized cervical cancer screening
- 1 January 2009
- journal article
- research article
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 88 (1) , 27-35
- https://doi.org/10.1080/00016340802566770
Abstract
Objective. Evaluate the efficacy of catch‐up HPV vaccination in sexually active young women and the potential impact of HPV vaccines on the practice of organized screening. Sample. (1) Women enrolled in the Future II study and (2) from a separate population‐based study in Iceland. Methods. (1) Analysis of cytological and histological results and colposcopic examinations among 710 women, aged 18–23, with less than five sexual partners, irrespectively of baseline HPV status at enrolment. (2) The impact on screening practice as determined by evaluating the distribution of 12 oncogenic HPV types in 582 cervical intraepithelial lesions (CIN 2–3) and cancer cases. Main outcome measures. (1) Distribution of evaluated parameters according to age at enrolment. (2) Age distribution of four HPV groups, within age classes and HPV groups: mean time to development of lesions, mean time to development of CIN 2–3+, cumulative frequency for CIN 2–3+ lesions after the last normal smear. Results. (1) After an average 52 months of post‐enrolment follow‐up, significant reductions in all evaluated parameters were observed in women aged 18–19 at enrolment. (2) Among women Conclusions. Catch‐up vaccination of younger women should be considered in the context of sexual practices and the effects of prevalent disease on observed vaccine efficacy. Current data do not support a change in the lower age limit or screening intervals for women.Keywords
This publication has 25 references indexed in Scilit:
- Prophylactic Efficacy of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Women with Virological Evidence of HPV InfectionThe Journal of Infectious Diseases, 2007
- Human Papillomavirus Vaccine Should Be Given before Sexual Debut for Maximum BenefitThe Journal of Infectious Diseases, 2007
- HPV genotypes in CIN 2‐3 lesions and cervical cancer: A population‐based studyInternational Journal of Cancer, 2007
- Is it rational to start population-based cervical cancer screening at or soon after age 20? Analysis of time trends in preinvasive and invasive diseasesEuropean Journal Of Cancer, 2007
- High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-upBritish Journal of Cancer, 2006
- Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancerInternational Journal of Gynecologic Cancer, 2004
- Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in FinlandJournal of General Virology, 2003
- Eligibility and willingness of young Icelandic women to participate in a HPV vaccination trialActa Obstetricia et Gynecologica Scandinavica, 2003
- High incidence of cervical human papillomavirus infection in women during their first sexual relationshipBJOG: An International Journal of Obstetrics and Gynaecology, 2002
- Trends in cervical intra-epithelial neoplasia in Iceland through 1995, Evaluation of targeted age groups and screening intervalsActa Obstetricia et Gynecologica Scandinavica, 1999